Discovery of potential aldose reductase inhibitors using in silico docking studies

被引：17

作者：

Madeswaran A. ^{[1
]}

Umamaheswari M. ^{[1
]}

Asokkumar K. ^{[1
]}

Sivashanmugam T. ^{[1
]}

Subhadradevi V. ^{[1
]}

Jagannath P. ^{[1
]}

机构：

[1] Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences

来源：

Oriental Pharmacy and Experimental Medicine | 2012年 / 12卷 / 2期

关键词：

Aldose reductase; Binding energy; Flavonoids; Inhibition constant; Intermolecular energy;

D O I：

10.1007/s13596-012-0065-3

中图分类号：

学科分类号：

摘要：

The primary objective of this study was to investigate the aldose reductase inhibitory activity of flavonoids using in silico docking studies. In this perspective, flavonoids like Apigenin, Baicalin, Daidzein, Epigallocatechin, Galangin, Genistein, Hesperitin, Naringenin, and Scopoletin were selected. Epalrestat, a known aldose reductase inhibitor was used as the standard. In silico docking studies were carried out using AutoDock 4. 2, based on the Lamarckian genetic algorithm principle. In the docking studies, three important parameters like binding energy, inhibition constant and intermolecular energy were determined. The results showed that all the selected flavonoids showed binding energy ranging between -9. 91 kcal/mol to -7. 52 kcal/mol when compared with that of the standard (-8. 73 kcal/mol). Intermolecular energy (-11. 40 kcal/mol to -8. 71 kcal/mol) and inhibition constant (54. 78 nM to 3. 10 μM) of the flavonoids also coincide with the binding energy. All the selected flavonoids contributed aldose reductase inhibitory activity because of its functional groups. These molecular docking analyses could lead to the further development of potent aldose reductase inhibitors for the treatment of diabetes. © 2012 Institute of Oriental Medicine, Kyung Hee University.

引用

页码：157 / 161

页数：4

共 21 条

[1]

Calderone V., Chevrier B., Zandt V.M., Lamour V., Howard E., Poterszman A., Barth P., Mitchler A., Lu J., Dvornik M.D., Klebe G., Kraemer O., Moorman R.A., Moras D., Podjarny A., The structure of human aldose reductase bound to the inhibitor IDD384, Acta Crystallogr D, 56, 5, pp. 536-540, (2000)

[2]

Cosconati S., Forli S., Perryman A.L., Harris R., Goodsell D.S., Olson A.J., Virtual screening with AutoDock: theory and practice, Expert Opin Drug Discov, 5, 6, pp. 597-607, (2010)

[3]

Cushnie T.P., Lamb A.J., Recent advances in understanding the antibacterial properties of flavonoids, Int J Antimicrob Agents, 38, 2, pp. 99-107, (2011)

[4]

Dong Y., Yang J., Ren X., Zhang H., He J., New aldose reductase inhibitors N99-596 A and B from streptomyces, J Antibiot, 58, pp. 737-739, (2005)

[5]

Gonzalez R., Ballester I., Et al., Effects of flavonoids and other polyphenols on inflammation, Crit Rev Food Sci Nutr, 51, 4, pp. 331-362, (2011)

[6]

Guzman A., Guerrero O.R., Inhibition of aldose reductase by herbs extracts and natural substances and their role in prevention of cataracts, Rev Cubana Plant Med, 10, pp. 3-4, (2005)

[7]

Hwang Y.C., Shaw S., Kaneko M., Et al., Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury, FASEB J, 19, pp. 795-797, (2005)

[8]

Lamba H.S., Bhargava C.S., Thakur M., Bhargava S., α- glucosidase and aldose reductase inhibitory activity in vitro and anti diabetic activity in vivo of tribulus terrestris l. (dunal), Int J Pharm Pharmac Sci, 3, 3, pp. 270-272, (2011)

[9]

Li Y., Li C., Xu Q., Kang W., Antioxidant, α-glucosidase inhibitory activities in vitro and alloxan-induced diabetic rats' protective effect of Indigofera stachyodes Lindl. root, J Med Plants Res, 5, 14, pp. 3321-3328, (2011)

[10]

Liu H.B., Wang Z.L., Qiao Y.X., Zhou J.J., Flavonoids with aldose reductase inhibiting activity: pharmacophoremodeling and implications for mechanism, Acta Phys Chim Sin, 23, pp. 25-35, (2007)

← 1 2 3 →